Alnylam Pharmaceuticals (ALNY) PT Raised to $125 at Needham & Company

Needham & Company analyst Alan Carr raised his price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $125.00 (from $85.00) while maintaining a Buy rating after the company announced positive top-line results from Phase 3 APOLLO trial in TTR Amyloidosis.

"Notably, primary mNIS+7 and key secondary Norfolk QOL-DN endpoint values improved from baseline, suggesting patisiran capable of more than simply slowing disease progression," Carr commented.

You May Also Be Interested In

• Boston Scientific (BSX) PT Raised to $83 at Stifel
• Lockheed Martin (LMT) PT Raised to $487 at Deutsche Bank
• HSBC Downgrades Anglo American Platinum Limited (AMS:SJ) (ANGPY) to Reduce